New pill targets Hard-to-Treat cancer mutation in early human test
NCT ID NCT07456046
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-stage trial is testing an experimental oral drug called D3S-003 in 42 people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Participants must have already tried standard treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
D3 Bio Investigative Site 1103
RECRUITINGRandwick, New South Wales, 2031, Australia
-
D3 Bio Investigative Site 1201
RECRUITINGSeoul, 03080, South Korea
-
D3 Bio Investigative Site 1202
RECRUITINGSeoul, 06591, South Korea
-
D3 Bio Investigative Site 1203
RECRUITINGSeoul, 03722, South Korea
-
D3 Bio Investigative Site 1402
RECRUITINGSan Antonio, Texas, 78229, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
D3S-003 (an oral tablet targeting KRAS G12D mutations)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have a specific KRAS mutation.
What could go wrong
This is a very early, small Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not shrink tumors or could cause side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.